Cosmos Health (COSM) Stock Price, Financials & Analysis

Key Stats

Market Cap16.33 Mn

P/E-0.67

P/S0.22

Div. Yield0.00

Total Debt (Qtr)15.14 Mn

Revenue Growth (1y) (Qtr)28.76

Add ratio to table…

About

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group that owns proprietary pharmaceutical and nutraceutical brands, manufactures and distributes generic and innovative medicines, produces biocides and medical devices, develops drug repurposing solutions and operates a telehealth platform. The company generates revenue from the sale of generic pharmaceuticals, nutraceutical supplements, biocide products, oncology drug candidates, licensing of…

The company generates revenue from the sale of generic pharmaceuticals, nutraceutical supplements, biocide products, oncology drug candidates, licensing of its AI driven drug repurposing platform, telehealth subscriptions and contract manufacturing for third parties.

The company operates through the following segments: Generic Medicines, Nutraceuticals, Biocides, Novel Oncology Drugs, Drug Repurposing, Telehealth Services.

Generic Medicines: Develops, manufactures and sells generic pharmaceutical products such as ASTO‑CHOL, Diorium, HEART‑FREE, LIPICHOL, Miltus, Newzypra, PNEUMO‑KAST, Sahar, VIVALCID and Diabit‑is in tablets, capsules, liquids, ointments and creams.
Nutraceuticals: Offers the Sky Premium Life® and Mediterranation® brands with approximately 165 SKUs covering vitamins, minerals, amino acids, herbal extracts for wellbeing, immunity, cardiovascular health, bones and joints, men’s and women’s health, beauty, digestive health, brain function, energy, mood, stress and sleep.
Biocides: Provides the C‑Sept® and C‑Scrub® brands, which combine chlorhexidine digluconate with isopropyl alcohol to deliver broad spectrum antimicrobial and antiseptic formulations for infection control.
Novel Oncology Drugs: Focuses on repurposed and innovative anticancer therapies targeting CNS, prostate, ovarian and colorectal cancers, including the obesity‑related compound CCX0722, a MALT1‑targeting agent for CNS cancer and TADs derivatives with multi targeted activity against resistant tumor cells.
Drug Repurposing: Operates the Cloudscreen® AI platform that analyzes proteomic and variomic data to identify new therapeutic uses for existing drugs, with patent applications filed for multiple sclerosis, glioma and hematologic malignancies.
Telehealth Services: Delivers the ZipDoctor platform, a direct to consumer subscription service providing 24/7 access to board certified physicians and licensed mental‑health counsellors via telephone or secured video chat in the United States with English and Spanish coverage.

Cosmos Health Inc. competes in highly regulated generic pharmaceutical, nutraceutical, biocide, oncology and telehealth markets against large pharmaceutical companies, generic manufacturers, nutraceutical retailers, biocide suppliers, oncology drug developers and telemedicine providers; its competitive advantages stem from vertical integration, proprietary brands, an AI driven repurposing platform, GMP and EMA manufacturing licenses, a broad product portfolio and the ability to launch new generic equivalents quickly.

The company serves retail pharmacies, hospitals, private clinics, wholesalers and governmental agencies across the European Union, the United Kingdom, the United Arab Emirates and increasingly North America, with no single customer accounting for 10% or more of its total consolidated revenue.

How Cosmos Health ranks

Ranked against the 669 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 23, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.61xMedian 17.0x 17^th
P/FCFNegative free cash flow −1.51xMedian 17.8x 26^th
P/Operating cash flowNegative operating cash flow −1.52xMedian 16.9x 25^th
P/S 0.20xMedian 9.11x 97^th
P/B 0.72xMedian 2.15x 80^th
P/Tangible book 1.09xMedian 2.38x 73^rd
EV/EBITDANegative EBITDA −1.67xMedian 16.1x 28^th
EV/EBITNegative EBIT −1.54xMedian 20.0x 31^st
EV/Revenue 0.38xMedian 6.53x 94^th
EV/FCFNegative free cash flow −2.85xMedian 19.5x 32^nd
EV/Operating cash flowNegative operating cash flow −2.87xMedian 16.5x 31^st
PEG (3Y EPS CAGR)Negative earnings −0.01Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 33.8%Median 10.3% 66^th
Revenue CAGR (3Y) 14.8%Median 10.2% 55^th
Gross profit growth (1Y) 39.7%Median 10.6% 74^th
Gross profit CAGR (3Y) 22.5%Median 10.7% 64^th
Operating income growth (1Y) −24.9%Median −0.1% 32^nd
Operating income CAGR (3Y) −12.5%Median 1.6% 32^nd
Net income growth (1Y) −58.7%Median −5.1% 25^th
Net income CAGR (3Y) −19.7%Median −0.5% 28^th
EPS growth (1Y) 45.7%Median 21.3% 65^th
EPS CAGR (3Y) 52.7%Median 25.3% 77^th
Operating cash flow growth (1Y) −119%Median 0.5% 8^th
Operating cash flow CAGR (3Y) 25.6%Median 2.4% 78^th
Free cash flow growth (1Y) −106%Median 0.5% 9^th
Free cash flow CAGR (3Y) 26.7%Median 3.3% 79^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 10.3%Median 74.0% 7^th
EBITDA margin −23.0%Median −216% 66^th
Operating margin −24.9%Median −230% 68^th
Pretax margin −33.1%Median −223% 67^th
Net margin −33.1%Median −230% 66^th
FCF margin −13.5%Median −168% 67^th
Operating cash flow margin −13.3%Median −157% 67^th
Return on equity −120%Median −53.6% 25^th
Return on assets −39.4%Median −42.1% 52^nd
Return on invested capital —Median −5.3% No data —
Return on capital employed −67.7%Median −46.0% 36^th
Asset turnover 1.19xMedian 0.18x 95^th
Cash conversion (OCF / net income)Net income is not positive 0.40xMedian 1.21x Not meaningful —
Stock comp / revenue 0.6%Median 27.5% 98^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 24.6%Median 20.0% 44^th
Debt / equity 0.73xMedian 0.26x 28^th
Net debt / EBITDAEBITDA is not positive −0.78xMedian 1.82x Not meaningful —
Debt / FCFFree cash flow is not positive −1.52xMedian 3.03x Not meaningful —
Liabilities / assets 66.4%Median 32.8% 29^th
Equity / assets 33.6%Median 67.2% 29^th
Interest coverage −7.80xMedian −10.2x 56^th
Current ratio 1.05xMedian 4.47x 16^th
Quick ratio 0.66xMedian 3.69x 14^th
Cash ratio 0.05xMedian 3.35x 5^th
Altman Z-score −2.76Median −0.61 40^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,140.21 Bn	42.69	14.31	54.91 Bn
2	JNJ	Johnson & Johnson	632.33 Bn	39.29	6.37	44.65 Bn
3	ABBV	AbbVie Inc.	500.02 Bn	79.24	7.77	70.82 Bn
4	MRK	Merck & Co., Inc.	355.31 Bn	111.98	5.34	53.91 Bn
5	NVS	Novartis Ag	300.67 Bn	19.06	5.49	9.59 Bn
6	AZN	Astrazeneca Plc	263.56 Bn	25.23	4.49	32.35 Bn
7	AMGN	Amgen Inc	237.81 Bn	27.20	6.24	57.30 Bn
8	COSM	Cosmos Health Inc.	0.02 Bn	-0.67	0.22	0.02 Bn

Cosmos Health COSM

About

Income Tax Authority Name Axis Breakdown of Revenue (2025)

Statement Business Segments Axis Breakdown of Revenue (2025)

How Cosmos Health ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Cosmos Health COSM

About

Income Tax Authority Name Axis Breakdown of Revenue (2025)

Statement Business Segments Axis Breakdown of Revenue (2025)

How Cosmos Health ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password